Israel Englander’s Indaptus Therapeutics INDP Stock Holding History

Israel Englander’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.8K	Buy	+11,586	New	+$29.2K	﹤0.01%	5649
2022 Q1	–	Sell	-1,359	Closed	-$217K	–	7164
2021 Q4	$217K	Buy	+1,359	New	+$252K	﹤0.01%	5844
2021 Q1	–	Sell	-419	Closed	-$162K	–	6201
2020 Q4	$162K	Buy	+419	New	+$183K	﹤0.01%	4917
2019 Q3	–	Sell	-18	Closed	-$174K	–	4354
2019 Q2	$174K	Buy	18 +13	+260%	+$164K	﹤0.01%	3792
2019 Q1	$80K	Buy	+5	New	+$87.6K	﹤0.01%	3873
2018 Q4	–	Sell	-21	Closed	-$262K	–	3941
2018 Q3	$262K	Sell	21 -10	-32%	-$95K	﹤0.01%	3541
2018 Q2	$308K	Buy	+31	New	+$344K	﹤0.01%	3378
2018 Q1	–	Sell	-121	Closed	-$1.39M	–	3849
2017 Q4	$1.39M	Buy	+121	New	+$1.87M	﹤0.01%	2501

Other funds holding INDP

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Israel Englander's INDP Position: Q2 2026 in Review

Israel Englander opened a new position in Indaptus Therapeutics (INDP) in Q2 2026: 11,586 shares worth $34.8K. The stake represents ﹤0.01% of the portfolio and ranks #5649 among its holdings. This is a return to the name: Israel Englander previously reported a position in INDP as recently as Q4 2021.

Israel Englander first reported a position in INDP in Q4 2017 and has held it in 8 quarters since. The position peaked at $1.39M in Q4 2017. 9 funds tracked by Wall St. Rank hold INDP as of Q2 2026.

Israel Englander held 11,586 shares of Indaptus Therapeutics worth $34.8K as of Q2 2026.
Indaptus Therapeutics was a new Israel Englander position in Q2 2026.
Indaptus Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5649 holding.
Israel Englander first reported a position in Indaptus Therapeutics in Q4 2017 and has held it in 8 quarters since.
Israel Englander's Indaptus Therapeutics position peaked at $1.39M in Q4 2017.
9 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.